

A novel dendritic cell subset involved in tumor immun

Nature Medicine

12, 214-219

DOI: 10.1038/nm1356

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Pathological role of Toll-like receptor signaling in cerebral malaria. <i>International Immunology</i> , 2006, 19, 67-79. | 1.8 | 144 |
| 2 | Dual role of macrophages in tumor growth and angiogenesis. <i>Journal of Leukocyte Biology</i> , 2006, 80, 705-713. | 1.5 | 255 |
| 3 | Analyses and Perspectives in Cancer immunotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2006, 60, 621-628. | 2.5 | 4 |
| 4 | Production of interferon- γ by myeloid cells – fact or fancy?. <i>Trends in Immunology</i> , 2006, 27, 282-290. | 2.9 | 101 |
| 6 | The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. <i>Immunological Reviews</i> , 2006, 214, 229-238. | 2.8 | 235 |
| 7 | Natural killer cells in viral infection: more than just killers. <i>Immunological Reviews</i> , 2006, 214, 239-250. | 2.8 | 77 |
| 8 | Role of Dendritic Cells in Sjogren's Syndrome. <i>Scandinavian Journal of Immunology</i> , 2006, 64, 219-226. | 1.3 | 29 |
| 9 | A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. <i>Nature Immunology</i> , 2006, 7, 1217-1224. | 7.0 | 403 |
| 10 | Is it a DC, is it an NK? No, it's an IKDC. <i>Nature Medicine</i> , 2006, 12, 167-168. | 15.2 | 30 |
| 11 | Oxygen deprivation provokes melanoma. <i>Nature Medicine</i> , 2006, 12, 168-169. | 15.2 | 6 |
| 12 | Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. <i>Nature Medicine</i> , 2006, 12, 207-213. | 15.2 | 374 |
| 15 | Cancer despite immunosurveillance: immunoselection and immunosubversion. <i>Nature Reviews Immunology</i> , 2006, 6, 715-727. | 10.6 | 1,108 |
| 16 | Proteomic identification of the wt-p53-regulated tumor cell secretome. <i>Oncogene</i> , 2006, 25, 7650-7661. | 2.6 | 65 |
| 17 | Selective Resistance of Tetraploid Cancer Cells against DNA Damage-Induced Apoptosis. <i>Annals of the New York Academy of Sciences</i> , 2006, 1090, 35-49. | 1.8 | 50 |
| 18 | Helper Roles of NK and CD8 ⁺ T Cells in the Induction of Tumor Immunity Polarized Dendritic Cells as Cancer Vaccines. <i>Immunologic Research</i> , 2006, 36, 137-146. | 1.3 | 56 |
| 19 | Dual immunoregulatory pathways of 4-1BB signaling. <i>Journal of Molecular Medicine</i> , 2006, 84, 726-736. | 1.7 | 52 |
| 20 | Tumor and viral recognition by natural killer cells receptors. <i>Seminars in Cancer Biology</i> , 2006, 16, 348-358. | 4.3 | 156 |
| 21 | The role of the NKG2D receptor for tumor immunity. <i>Seminars in Cancer Biology</i> , 2006, 16, 333-343. | 4.3 | 125 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 22 | Imatinib Mesylate "Uncovering a Fast Track to Adaptive Immunity. <i>New England Journal of Medicine</i> , 2006, 354, 2282-2284. | 13.9 | 17 |
| 23 | Medical treatments for hepatocellular carcinoma (HCC): what's next?. <i>Annals of Oncology</i> , 2006, 17, x308-x314. | 0.6 | 26 |
| 24 | Combined Stimulation with Interleukin-18 and CpG Induces Murine Natural Killer Dendritic Cells to Produce IFN- γ and Inhibit Tumor Growth. <i>Cancer Research</i> , 2006, 66, 10497-10504. | 0.4 | 67 |
| 25 | Glycolipid α -C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 11252-11257. | 3.3 | 159 |
| 26 | T Cell-Dependent Activation of Dendritic Cells Requires IL-12 and IFN- γ Signaling in T Cells. <i>Journal of Immunology</i> , 2006, 177, 3625-3634. | 0.4 | 35 |
| 27 | Effects of LPS-mediated bystander activation in the innate immune system. <i>Journal of Leukocyte Biology</i> , 2006, 80, 1251-1261. | 1.5 | 24 |
| 28 | Preferential Induction of CD4+ T Cell Responses through In Vivo Targeting of Antigen to Dendritic Cell-Associated C-Type Lectin-1. <i>Journal of Immunology</i> , 2006, 177, 2276-2284. | 0.4 | 162 |
| 29 | Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers. <i>Endocrine-Related Cancer</i> , 2006, 13, 779-795. | 1.6 | 30 |
| 30 | NK Dendritic Cells Expanded in IL-15 Exhibit Antitumor Responses In Vivo. <i>Journal of Immunology</i> , 2007, 179, 4654-4660. | 0.4 | 22 |
| 31 | Regulation of Tumor Cell Sensitivity to TRAIL-Induced Apoptosis by the Metastatic Suppressor Raf Kinase Inhibitor Protein via Yin Yang 1 Inhibition and Death Receptor 5 Up-Regulation. <i>Journal of Immunology</i> , 2007, 179, 5441-5453. | 0.4 | 101 |
| 32 | HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN- α . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 17453-17458. | 3.3 | 147 |
| 33 | Dendritic Cells Trigger Tumor Cell Death by a Nitric Oxide-Dependent Mechanism. <i>Journal of Immunology</i> , 2007, 179, 812-818. | 0.4 | 35 |
| 34 | The Lipopolysaccharide Adjuvant Effect on T Cells Relies on Nonoverlapping Contributions from the MyD88 Pathway and CD11c+ Cells. <i>Journal of Immunology</i> , 2007, 179, 6524-6535. | 0.4 | 34 |
| 35 | Development and function of murine B220+CD11c+NK1.1+ cells identify them as a subset of NK cells. <i>Journal of Experimental Medicine</i> , 2007, 204, 2561-2568. | 4.2 | 150 |
| 36 | CD11c ^{lo} B220+ interferon-producing killer dendritic cells are activated natural killer cells. <i>Journal of Experimental Medicine</i> , 2007, 204, 2569-2578. | 4.2 | 140 |
| 37 | Cross-linking a mAb to NKR-P2/NKG2D on dendritic cells induces their activation and maturation leading to enhanced anti-tumor immune response. <i>International Immunology</i> , 2007, 19, 591-607. | 1.8 | 19 |
| 38 | Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. <i>European Respiratory Journal</i> , 2007, 29, 462-468. | 3.1 | 162 |
| 39 | 947; 948; T Cells and Dendritic Cells: Close Partners and Biological Adjuvants for New Therapies. <i>Current Molecular Medicine</i> , 2007, 7, 658-673. | 0.6 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 40 | Dendritic Cells: More Than Just Adaptive Immunity Inducers?. <i>Current Immunology Reviews</i> , 2007, 3, 17-22. | 1.2 | 2 |
| 41 | CD8 T Cell Help for Innate Antitumor Immunity. <i>Journal of Immunology</i> , 2007, 179, 6651-6662. | 0.4 | 94 |
| 42 | Human Allogeneic and Murine Xenogeneic Dendritic Cells Are Cytotoxic to Human Tumor Cells via Two Distinct Pathways. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007, 22, 672-683. | 0.7 | 6 |
| 43 | Cutting Edge: Conventional Dendritic Cells Are the Critical APC Required for the Induction of Experimental Cerebral Malaria. <i>Journal of Immunology</i> , 2007, 178, 6033-6037. | 0.4 | 104 |
| 44 | The pressure mounts on lung dendritic cells. <i>European Respiratory Journal</i> , 2007, 29, 435-437. | 3.1 | 4 |
| 45 | Therapy-Induced Tumor Immunosurveillance Involves IFN-Producing Killer Dendritic Cells: Figure 1.. <i>Cancer Research</i> , 2007, 67, 851-853. | 0.4 | 33 |
| 46 | Cross-Talk between T Cells and Innate Immune Cells Is Crucial for IFN- γ -Dependent Tumor Rejection. <i>Journal of Immunology</i> , 2007, 179, 1568-1576. | 0.4 | 38 |
| 47 | Characterization of Early Gamma Interferon (IFN- γ) Expression during Murine Listeriosis: Identification of NK1.1 + CD11c + Cells as the Primary IFN- γ -Expressing Cells. <i>Infection and Immunity</i> , 2007, 75, 1167-1176. | 1.0 | 17 |
| 48 | Putative IKDCs are functionally and developmentally similar to natural killer cells, but not to dendritic cells. <i>Journal of Experimental Medicine</i> , 2007, 204, 2579-2590. | 4.2 | 108 |
| 49 | Natural killer dendritic cells are an intermediate of developing dendritic cells. <i>Journal of Leukocyte Biology</i> , 2007, 81, 1422-1433. | 1.5 | 28 |
| 50 | The Kinase Inhibitor Imatinib - An Immunosuppressive Drug?. <i>Current Cancer Drug Targets</i> , 2007, 7, 251-258. | 0.8 | 23 |
| 51 | Targeting Human $\gamma\delta$ T Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer. <i>Cancer Research</i> , 2007, 67, 7450-7457. | 0.4 | 443 |
| 52 | Leveraging the Immune System during Chemotherapy: Moving Calreticulin to the Cell Surface Converts Apoptotic Death from "Silent" to Immunogenic. <i>Cancer Research</i> , 2007, 67, 7941-7944. | 0.4 | 134 |
| 53 | In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides. <i>Blood</i> , 2007, 109, 2008-2013. | 0.6 | 42 |
| 54 | Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. <i>Blood</i> , 2007, 109, 2791-2793. | 0.6 | 210 |
| 55 | Production of interferons by dendritic cells, plasmacytoid cells, natural killer cells, and interferon-producing killer dendritic cells. <i>Blood</i> , 2007, 109, 1165-1173. | 0.6 | 131 |
| 56 | Interferon-producing killer dendritic cells (IKDCs) arise via a unique differentiation pathway from primitive c-kit ⁺ CD62L ⁺ lymphoid progenitors. <i>Blood</i> , 2007, 109, 4825-4931. | 0.6 | 71 |
| 57 | CD4 cells can be more efficient at tumor rejection than CD8 cells. <i>Blood</i> , 2007, 109, 5346-5354. | 0.6 | 373 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 58 | Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. <i>Blood</i> , 2007, 110, 4037-4046. | 0.6 | 94 |
| 59 | Immune Stimulatory Features of Classical Chemotherapy. , 2007, , 235-256. | | 3 |
| 60 | Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells. <i>Melanoma Research</i> , 2007, 17, 169-176. | 0.6 | 21 |
| 61 | An Essential Role for IFN- γ in Regulation of Alloreactive CD8 T Cells Following Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 46-55. | 2.0 | 40 |
| 62 | Interferon- γ is produced by another player of innate immune responses: The interferon-producing killer dendritic cell (IKDC). <i>Biochimie</i> , 2007, 89, 872-877. | 1.3 | 24 |
| 63 | Interferon, a growing cytokine family: 50 years of interferon research. <i>Biochimie</i> , 2007, 89, 713-718. | 1.3 | 93 |
| 64 | Natural Killer or Dendritic: What's in a Name?. <i>Immunity</i> , 2007, 26, 11-16. | 6.6 | 85 |
| 65 | The Protean Nature of Cells in the B Lymphocyte Lineage. <i>Immunity</i> , 2007, 26, 703-714. | 6.6 | 216 |
| 66 | Development of Dendritic-Cell Lineages. <i>Immunity</i> , 2007, 26, 741-750. | 6.6 | 300 |
| 67 | Alveolar Macrophages Are the Primary Interferon- γ Producer in Pulmonary Infection with RNA Viruses. <i>Immunity</i> , 2007, 27, 240-252. | 6.6 | 340 |
| 68 | When killers become helpers. <i>Trends in Immunology</i> , 2007, 28, 201-206. | 2.9 | 113 |
| 69 | Linfopoyesis temprana en mÃ©dula Ã©sea adulta. <i>Inmunologia (Barcelona, Spain: 1987)</i> , 2007, 26, 135-144. | 0.1 | 1 |
| 70 | Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?. <i>Current Opinion in Immunology</i> , 2007, 19, 203-208. | 2.4 | 270 |
| 71 | Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 599-615. | 1.4 | 22 |
| 72 | Dendritic Cells in the Kidney. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 2628-2635. | 3.0 | 74 |
| 73 | Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. <i>Journal of Experimental Medicine</i> , 2007, 204, 1441-1451. | 4.2 | 317 |
| 74 | Monocyte derived dendritic cells generated by IFN- γ acquire mature dendritic and natural killer cell properties as shown by gene expression analysis. <i>Journal of Translational Medicine</i> , 2007, 5, 46. | 1.8 | 70 |
| 75 | Immunosurveillance: Innate and Adaptive Antitumor Immunity. , 2007, , 29-41. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 76 | TRAIL: a multifunctional cytokine. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 3813. | 3.0 | 114 |
| 77 | Regulation of natural killer cell activity. <i>Current Opinion in Immunology</i> , 2007, 19, 46-54. | 2.4 | 51 |
| 78 | How Ebola and Marburg viruses battle the immune system. <i>Nature Reviews Immunology</i> , 2007, 7, 556-567. | 10.6 | 125 |
| 79 | Promiscuity and the single receptor: NKG2D. <i>Nature Reviews Immunology</i> , 2007, 7, 737-744. | 10.6 | 352 |
| 80 | Developmental pathways that generate natural-killer-cell diversity in mice and humans. <i>Nature Reviews Immunology</i> , 2007, 7, 703-714. | 10.6 | 362 |
| 81 | Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity?. <i>British Journal of Haematology</i> , 2007, 136, 539-548. | 1.2 | 107 |
| 82 | Î³δ T cells: novel initiators of adaptive immunity. <i>Immunological Reviews</i> , 2007, 215, 89-102. | 2.8 | 70 |
| 83 | Dendritic cell subsets in health and disease. <i>Immunological Reviews</i> , 2007, 219, 118-142. | 2.8 | 370 |
| 84 | Innate VÎ±14⁺ natural killer T cells mature dendritic cells, leading to strong adaptive immunity. <i>Immunological Reviews</i> , 2007, 220, 183-198. | 2.8 | 158 |
| 85 | The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. <i>Immunological Reviews</i> , 2007, 220, 47-59. | 2.8 | 491 |
| 86 | Virus-based immunotherapy of cancer: what do we know and where are we going?. <i>Apmis</i> , 2007, 115, 1177-1193. | 0.9 | 4 |
| 87 | Heightened Expression of the Cytotoxicity Receptor NKG2D Correlates with Acute and Chronic Nephropathy After Kidney Transplantation. <i>American Journal of Transplantation</i> , 2007, 7, 423-433. | 2.6 | 56 |
| 88 | Hepatocellular Carcinoma (HCC): An Update. <i>Seminars in Oncology</i> , 2007, 34, S12-S20. | 0.8 | 57 |
| 89 | Emerging role of dendritic cells in respiratory viral infection. <i>Journal of Molecular Medicine</i> , 2007, 85, 1057-1068. | 1.7 | 53 |
| 91 | NK cells rapidly remove B16F10 tumor cells in a perforin and interferon-gamma independent manner in vivo. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1153-1161. | 2.0 | 49 |
| 92 | Robust anti-tumor immunity and memory in Rag-1-deficient mice following adoptive transfer of cytokine-primed splenocytes and tumor CD80 expression. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1955-1965. | 2.0 | 4 |
| 93 | The role of dendritic cells in the immunopathogenesis of psoriasis. <i>Archives of Dermatological Research</i> , 2007, 299, 359-366. | 1.1 | 57 |
| 94 | Dendritic cells: still a promising tool for cancer immunotherapy. <i>Clinical and Translational Oncology</i> , 2007, 9, 77-82. | 1.2 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 95 | Links between innate and cognate tumor immunity. <i>Current Opinion in Immunology</i> , 2007, 19, 224-231. | 2.4 | 59 |
| 96 | Natural killer cells: from CD3 ⁺ NKp46 ⁺ to post-genomics meta-analyses. <i>Current Opinion in Immunology</i> , 2007, 19, 365-372. | 2.4 | 117 |
| 97 | Transient downregulation of monocyte-derived dendritic-cell differentiation, function, and survival during tumoral progression and regression in an in vivo canine model of transmissible venereal tumor. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 479-491. | 2.0 | 36 |
| 98 | Transient activation of tumor-associated T-effector/memory cells promotes tumor eradication via NK-cell recruitment: minimal role for long-term T-cell immunity in cure of metastatic disease. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 997-1005. | 2.0 | 14 |
| 100 | A novel cell subset: Interferon-producing killer dendritic cells. <i>Science in China Series C: Life Sciences</i> , 2008, 51, 671-675. | 1.3 | 2 |
| 101 | Carcinogenesis. Improved knowledge and new concepts. <i>Oncologie</i> , 2008, 10, 319-347. | 0.2 | 3 |
| 102 | Use of ultraviolet-light irradiated multiple myeloma cells as immunogens to generate tumor-specific cytolytic T lymphocytes. <i>Journal of Immune Based Therapies and Vaccines</i> , 2008, 6, 2. | 2.4 | 3 |
| 103 | IL-10 and the resolution of infections. <i>Journal of Pathology</i> , 2008, 214, 224-230. | 2.1 | 58 |
| 104 | In vivo conversion of BM plasmacytoid DC into CD11b ⁺ conventional DC during virus infection. <i>European Journal of Immunology</i> , 2008, 38, 3388-3394. | 1.6 | 23 |
| 105 | Killer dendritic cells: IKDC and the others. <i>Current Opinion in Immunology</i> , 2008, 20, 558-565. | 2.4 | 35 |
| 106 | TLR9 as a key receptor for the recognition of DNA ⁺ . <i>Advanced Drug Delivery Reviews</i> , 2008, 60, 795-804. | 6.6 | 296 |
| 107 | Interleukin-15 liver gene transfer increases the number and function of IKDCs and NK cells. <i>Gene Therapy</i> , 2008, 15, 473-483. | 2.3 | 20 |
| 108 | Topical CpG Enhances the Response of Murine Malignant Melanoma to Dacarbazine. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2204-2210. | 0.3 | 24 |
| 109 | Innate lymphocyte and dendritic cell cross-talk: a key factor in the regulation of the immune response. <i>Clinical and Experimental Immunology</i> , 2008, 152, 219-226. | 1.1 | 64 |
| 110 | The Janus face of dendritic cells in cancer. <i>Oncogene</i> , 2008, 27, 5920-5931. | 2.6 | 80 |
| 111 | Natural killer cell-directed therapies: moving from unexpected results to successful strategies. <i>Nature Immunology</i> , 2008, 9, 486-494. | 7.0 | 265 |
| 112 | Interleukin 21: combination strategies for cancer therapy. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 231-240. | 21.5 | 88 |
| 113 | Immunological aspects of cancer chemotherapy. <i>Nature Reviews Immunology</i> , 2008, 8, 59-73. | 10.6 | 1,374 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 114 | Evolving views on the genealogy of B cells. <i>Nature Reviews Immunology</i> , 2008, 8, 95-106. | 10.6 | 92 |
| 115 | The "kiss of death"™ by dendritic cells to cancer cells. <i>Cell Death and Differentiation</i> , 2008, 15, 58-69. | 5.0 | 65 |
| 116 | Killer dendritic cells: mechanisms of action and therapeutic implications for cancer. <i>Cell Death and Differentiation</i> , 2008, 15, 51-57. | 5.0 | 34 |
| 117 | Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. <i>Cell Death and Differentiation</i> , 2008, 15, 39-50. | 5.0 | 141 |
| 118 | Tumor stress, cell death and the ensuing immune response. <i>Cell Death and Differentiation</i> , 2008, 15, 21-28. | 5.0 | 77 |
| 119 | Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. <i>Immunology</i> , 2008, 123, 575-583. | 2.0 | 125 |
| 120 | Neuroendocrine factors alter host defense by modulating immune function. <i>Cellular Immunology</i> , 2008, 252, 7-15. | 1.4 | 97 |
| 121 | Cutaneous Dendritic Cells in Health and Disease. , 2008, , 119-130. | | 0 |
| 122 | NOD/Shi-scid IL2r ³ null (NOG) Mice More Appropriate for Humanized Mouse Models. <i>Current Topics in Microbiology and Immunology</i> , 2008, 324, 53-76. | 0.7 | 106 |
| 123 | Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. <i>Genome Biology</i> , 2008, 9, R17. | 13.9 | 472 |
| 124 | Division of labor between dendritic cell subsets of the lung. <i>Mucosal Immunology</i> , 2008, 1, 442-450. | 2.7 | 151 |
| 125 | Cancer is not just a disease of a tissue: It is a host disease. <i>Annales D'Endocrinologie</i> , 2008, 69, 151-152. | 0.6 | 2 |
| 126 | Circulating HLA-DR+ natural killer cells have potent lytic ability and weak antigen-presenting cell function. <i>Human Immunology</i> , 2008, 69, 469-474. | 1.2 | 25 |
| 127 | Mechanisms of dendritic cell-based vaccination against infection. <i>International Journal of Medical Microbiology</i> , 2008, 298, 11-20. | 1.5 | 46 |
| 128 | Immunobiology of Dendritic Cells in Cancer. , 2008, , 101-130. | | 2 |
| 129 | Dendritic cells dysfunction in tumour environment. <i>Cancer Letters</i> , 2008, 272, 186-196. | 3.2 | 57 |
| 130 | Dendritic cells and innate defense against tumor cells. <i>Cytokine and Growth Factor Reviews</i> , 2008, 19, 79-92. | 3.2 | 49 |
| 131 | NKG2D ligands in tumor immunity. <i>Oncogene</i> , 2008, 27, 5944-5958. | 2.6 | 355 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 132 | Tumour immunity: effector response to tumour and role of the microenvironment. <i>Lancet, The</i> , 2008, 371, 771-783. | 6.3 | 476 |
| 133 | Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update. <i>Cytotherapy</i> , 2008, 10, 633-641. | 0.3 | 46 |
| 134 | Tumour-immune cell interactions modulated by chemokines. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 269-290. | 1.4 | 37 |
| 135 | The Critical Role of IL-15 in the Antitumor Effects Mediated by the Combination Therapy Imatinib and IL-2. <i>Journal of Immunology</i> , 2008, 180, 6477-6483. | 0.4 | 44 |
| 136 | T-Bet Plays a Key Role in NK-Mediated Control of Melanoma Metastatic Disease. <i>Journal of Immunology</i> , 2008, 180, 8004-8010. | 0.4 | 86 |
| 137 | The Ischemia-Responsive Protein 94 (Irp94) Activates Dendritic Cells through NK Cell Receptor Protein-2/NK Group 2 Member D (NKR-P2/NKG2D) Leading to Their Maturation. <i>Journal of Immunology</i> , 2008, 180, 1117-1130. | 0.4 | 12 |
| 138 | Rat CD4+CD8+Macrophages Kill Tumor Cells through an NKG2D- and Granzyme/Perforin-Dependent Mechanism. <i>Journal of Immunology</i> , 2008, 180, 2999-3006. | 0.4 | 22 |
| 139 | Bone Marrow-Derived IFN-Producing Killer Dendritic Cells Account for the Tumoricidal Activity of Unpulsed Dendritic Cells. <i>Journal of Immunology</i> , 2008, 181, 6654-6663. | 0.4 | 21 |
| 140 | Antiviral NK cell responses in HIV infection: I. NK cell receptor genes as determinants of HIV resistance and progression to AIDS. <i>Journal of Leukocyte Biology</i> , 2008, 84, 1-26. | 1.5 | 75 |
| 141 | The 2007 Marie Curie prize: the linear no threshold relationship and advances in our understanding of carcinogenesis. <i>International Journal of Low Radiation</i> , 2008, 5, 173. | 0.1 | 17 |
| 142 | Strategies of Natural Killer (NK) Cell Recognition and Their Roles in Tumor Immunosurveillance. , 2008, , 37-81. | | 1 |
| 143 | Two Novel NKG2D Ligands of the Mouse H60 Family with Differential Expression Patterns and Binding Affinities to NKG2D. <i>Journal of Immunology</i> , 2008, 180, 1678-1685. | 0.4 | 83 |
| 144 | Dendritic Cells as Killers: Mechanistic Aspects and Potential Roles. <i>Journal of Immunology</i> , 2008, 181, 11-16. | 0.4 | 34 |
| 145 | IFN- γ Skews Monocytes into CD56+-Expressing Dendritic Cells with Potent Functional Activities In Vitro and In Vivo. <i>Journal of Immunology</i> , 2008, 180, 1462-1470. | 0.4 | 103 |
| 146 | Killer Dendritic Cells Link Innate and Adaptive Immunity against Established Osteosarcoma in Rats. <i>Cancer Research</i> , 2008, 68, 9433-9440. | 0.4 | 32 |
| 147 | Temporal Regulation of Interleukin-12p70 (IL-12p70) and IL-12-Related Cytokines in Splenic Dendritic Cell Subsets during <i>Leishmania donovani</i> Infection. <i>Infection and Immunity</i> , 2008, 76, 239-249. | 1.0 | 36 |
| 148 | The anticancer immune response: indispensable for therapeutic success?. <i>Journal of Clinical Investigation</i> , 2008, 118, 1991-2001. | 3.9 | 520 |
| 149 | Immunosurveillance of Lung Melanoma Metastasis in EBI-3-Deficient Mice Mediated by CD8+ T Cells. <i>Journal of Immunology</i> , 2008, 181, 6148-6157. | 0.4 | 29 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 150 | Effect of Interleukin-2 Pretreatment on Paclitaxel Absorption and Tissue Disposition after Oral and Intravenous Administration in Mice. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1729-1735. | 1.7 | 7 |
| 151 | Killer Dendritic Cells and their Potential Role in Immunotherapy. <i>Hormone and Metabolic Research</i> , 2008, 40, 75-81. | 0.7 | 15 |
| 152 | Advances in Cellular Therapy. <i>Hormone and Metabolic Research</i> , 2008, 40, 73-74. | 0.7 | 0 |
| 153 | Dendritic Cell Based Immunotherapy - A Promising Therapeutic Approach for Endocrine Malignancies. <i>Hormone and Metabolic Research</i> , 2008, 40, 89-98. | 0.7 | 15 |
| 155 | Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. <i>Blood</i> , 2008, 111, 2170-2180. | 0.6 | 102 |
| 156 | Lymphoid precursors are directed to produce dendritic cells as a result of TLR9 ligation during herpes infection. <i>Blood</i> , 2008, 112, 3753-3761. | 0.6 | 108 |
| 157 | The dilemma of anticancer therapy: tumor-specific versus immune effects. <i>Blood</i> , 2008, 112, 4364-4365. | 0.6 | 10 |
| 158 | Intramammary Application of Non-Methylated-CpG Oligodeoxynucleotides (CpG) Inhibits both Local and Systemic Mammary Carcinogenesis in Female BALB/c Her-2/neu Transgenic Mice. <i>Current Cancer Drug Targets</i> , 2008, 8, 230-242. | 0.8 | 13 |
| 159 | Trans-Presentation of IL-15 Dictates IFN-Producing Killer Dendritic Cells Effector Functions. <i>Journal of Immunology</i> , 2008, 180, 7887-7897. | 0.4 | 47 |
| 160 | IFN-producing Killer Dendritic Cells Contribute to the Inhibitory Effect of Poly I:C on the Progression of Murine Melanoma. <i>Journal of Immunotherapy</i> , 2008, 31, 555-562. | 1.2 | 18 |
| 161 | New Roles for Mononuclear Phagocytes in Cancer Biology. <i>Journal of Pediatric Hematology/Oncology</i> , 2008, 30, 584-591. | 0.3 | 6 |
| 162 | Lysates of <i>S. pyogenes</i> Serotype M49 Induce Pancreatic Tumor Growth Delay by Specific and Unspecific Antitumor Immune Responses. <i>Journal of Immunotherapy</i> , 2008, 31, 704-713. | 1.2 | 19 |
| 164 | Neonatal T-Cell Immunity and its Regulation by Innate Immunity and Dendritic Cells. , 2008, , 208-230. | | 0 |
| 165 | CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. <i>Journal of Clinical Investigation</i> , 2008, 118, 3751-3761. | 3.9 | 56 |
| 167 | CD2 Distinguishes Two Subsets of Human Plasmacytoid Dendritic Cells with Distinct Phenotype and Functions. <i>Journal of Immunology</i> , 2009, 182, 6815-6823. | 0.4 | 162 |
| 168 | An Accessory Role for B Cells in the IL-12-Induced Activation of Resting Mouse NK Cells. <i>Journal of Immunology</i> , 2009, 183, 3608-3615. | 0.4 | 8 |
| 169 | Dendritic Cell and NK Cell Reciprocal Cross Talk Promotes Gamma Interferon-Dependent Immunity to Blood-Stage <i>Plasmodium chabaudi</i> AS Infection in Mice. <i>Infection and Immunity</i> , 2009, 77, 770-782. | 1.0 | 89 |
| 170 | Migratory and Antigen Presentation Functions of IFN-Producing Killer Dendritic Cells. <i>Cancer Research</i> , 2009, 69, 6598-6606. | 0.4 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 171 | Dendritic Cells and their Receptors in Antitumor Immune Response. <i>Current Molecular Medicine</i> , 2009, 9, 708-724. | 0.6 | 5 |
| 172 | NFATc1 Mediates Toll-Like Receptor-Independent Innate Immune Responses during <i>Trypanosoma cruzi</i> Infection. <i>PLoS Pathogens</i> , 2009, 5, e1000514. | 2.1 | 31 |
| 173 | IFN-Producing Killer Dendritic Cells Are Antigen-Presenting Cells Endowed with T-Cell Cross-Priming Capacity. <i>Cancer Research</i> , 2009, 69, 6607-6614. | 0.4 | 22 |
| 174 | The Dendritic Cell-like Functions of IFN-Producing Killer Dendritic Cells Reside in the CD11b+ Subset and Are Licensed by Tumor Cells. <i>Cancer Research</i> , 2009, 69, 6590-6597. | 0.4 | 26 |
| 175 | Cutting Edge: Genetic Characterization of IFN-Producing Killer Dendritic Cells. <i>Journal of Immunology</i> , 2009, 182, 5193-5197. | 0.4 | 18 |
| 176 | LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis. <i>Journal of Immunology</i> , 2009, 182, 1885-1891. | 0.4 | 311 |
| 177 | Subversion of Pulmonary Dendritic Cell Function by Paramyxovirus Infections. <i>Journal of Immunology</i> , 2009, 182, 3072-3083. | 0.4 | 70 |
| 178 | New insight into the mechanism of action of IVIg: the role of dendritic cells. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 245-248. | 1.9 | 43 |
| 180 | Dendritic Cell-Associated Osteoclastogenesis and Bone Loss. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2009, 7, 269-284. | 1.3 | 1 |
| 181 | NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 575-587. | 2.0 | 27 |
| 182 | Following TRAIL's path in the immune system. <i>Immunology</i> , 2009, 127, 145-154. | 2.0 | 254 |
| 183 | Improvement of a dendritic cell-based tumour vaccine by an influenza virus. <i>European Journal of Clinical Investigation</i> , 2009, 39, 1000-1009. | 1.7 | 2 |
| 184 | Dual Therapeutic Efficacy of Vinblastine as a Unique Chemotherapeutic Agent Capable of Inducing Dendritic Cell Maturation. <i>Cancer Research</i> , 2009, 69, 6987-6994. | 0.4 | 113 |
| 185 | Human embryo immune escape mechanisms rediscovered by the tumor. <i>Immunobiology</i> , 2009, 214, 61-76. | 0.8 | 17 |
| 186 | Hemocytes of the carpet shell clam (<i>Ruditapes decussatus</i>) and the Manila clam (<i>Ruditapes</i>) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 182 T | 1.7 | 201 |
| 187 | Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. <i>Journal of Experimental Medicine</i> , 2009, 206, 549-559. | 4.2 | 488 |
| 188 | Targeting Toll-Like Receptor for the Induction of Immune and Antitumor Responses. , 2009, , 301-318. | | 0 |
| 190 | Activated Human $\hat{3}\hat{7}$ T Cells as Stimulators of Specific CD8+ T-cell Responses to Subdominant Epstein Barr Virus Epitopes. <i>Journal of Immunotherapy</i> , 2009, 32, 310-321. | 1.2 | 34 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 191 | PD-1 on dendritic cells impedes innate immunity against bacterial infection. <i>Blood</i> , 2009, 113, 5811-5818. | 0.6 | 179 |
| 192 | Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4. <i>Blood</i> , 2009, 114, 4823-4831. | 0.6 | 91 |
| 193 | Dendritic Cells: A New Player in Osteoimmunology. <i>Current Molecular Medicine</i> , 2009, 9, 893-910. | 0.6 | 32 |
| 194 | TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges. <i>Reviews on Recent Clinical Trials</i> , 2009, 4, 34-41. | 0.4 | 134 |
| 195 | Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. <i>Haematologica</i> , 2009, 94, 135-139. | 1.7 | 137 |
| 196 | Killer dendritic cells and their potential for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1-11. | 2.0 | 44 |
| 197 | CD11c+CD8+ T cells: Two-faced adaptive immune regulators. <i>Cellular Immunology</i> , 2010, 264, 18-22. | 1.4 | 36 |
| 198 | Transcriptional regulation of natural killer cell development. <i>Current Opinion in Immunology</i> , 2010, 22, 193-198. | 2.4 | 25 |
| 199 | Functional diversity of stem and progenitor cells with B α lymphopoietic potential. <i>Immunological Reviews</i> , 2010, 237, 10-21. | 2.8 | 41 |
| 200 | Natural Killer Cells Accumulate in Lung-draining Lymph Nodes and Regulate Airway Eosinophilia in a Murine Model of Asthma. <i>Scandinavian Journal of Immunology</i> , 2010, 72, 118-127. | 1.3 | 31 |
| 201 | Proliferating NK cells in response to IL-15 do not upregulate surface B220 in vivo. <i>Gene Therapy</i> , 2010, 17, 687-689. | 2.3 | 1 |
| 202 | Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. <i>Immunological Reviews</i> , 2010, 234, 142-162. | 2.8 | 345 |
| 203 | Has the Practice of Radiation Oncology for Locally Advanced and Metastatic Non-Small-Cell Lung Cancer Changed in Canada?. <i>Current Oncology</i> , 2010, 17, 33-40. | 0.9 | 107 |
| 204 | Peroxynitrite-Dependent Killing of Cancer Cells and Presentation of Released Tumor Antigens by Activated Dendritic Cells. <i>Journal of Immunology</i> , 2010, 184, 1876-1884. | 0.4 | 58 |
| 205 | Imatinib Mesylate (Gleevec $\text{\textcircled{C}}$): Targeted Therapy Against Cancer with Immune Properties. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2010, 10, 1-7. | 0.6 | 5 |
| 206 | Interferon-producing killer dendritic cells (IKDC)., 2010, , 41-53. | | 0 |
| 207 | K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate. <i>Clinical Cancer Research</i> , 2010, 16, 338-347. | 3.2 | 106 |
| 208 | ROLE OF NATURAL KILLER DENDRITIC CELLS IN HOST RESISTANCE AGAINST PSEUDOMONAS AERUGINOSA INFECTION AFTER THERMAL INJURY IN MICE. <i>Shock</i> , 2010, 34, 83-89. | 1.0 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 209 | Tumor immunogenicity and responsiveness to cancer vaccine therapy: The state of the art. <i>Seminars in Immunology</i> , 2010, 22, 105-112. | 2.7 | 44 |
| 210 | Interferon producing killer dendritic cells (IKDC): A matter of controversy. <i>Inmunologia (Barcelona)</i> , Tj ETQq1 1 0.784314 rgBT /Overlo | 0.1 | 1 |
| 211 | Developmental stages and pathways of NK cell maturation. , 2010, , 3-24. | | 1 |
| 212 | Tolerogen-induced interferon-producing killer dendritic cells (IKDCs) protect against EAE. <i>Journal of Autoimmunity</i> , 2011, 37, 328-341. | 3.0 | 17 |
| 213 | Harnessing dendritic cells in cancer. <i>Seminars in Immunology</i> , 2011, 23, 42-49. | 2.7 | 53 |
| 215 | Anticancer effects of imatinib via immunostimulation. <i>Nature Medicine</i> , 2011, 17, 1050-1051. | 15.2 | 23 |
| 216 | Isolation of Mouse Lung Dendritic Cells. <i>Journal of Visualized Experiments</i> , 2011, , . | 0.2 | 12 |
| 217 | Natural killer cell differentiation by myeloid progenitors. <i>Blood</i> , 2011, 117, 3548-3558. | 0.6 | 107 |
| 218 | Cancer Gene Therapy via NKG2D and FAS Pathways. , 2011, , . | | 1 |
| 219 | Tirosin Kinase Inhibitors in Chronic Graft versus Host Disease: From Bench to Bedside. <i>Scientific World Journal, The</i> , 2011, 11, 1908-1931. | 0.8 | 26 |
| 220 | Innate IFN- β -Producing Cells in the Spleen of Mice Early after <i>Listeria monocytogenes</i> Infection: Importance of Microenvironment of the Cells Involved in the Production of Innate IFN- β . <i>Frontiers in Immunology</i> , 2011, 2, 26. | 2.2 | 17 |
| 221 | Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. <i>Nature Medicine</i> , 2011, 17, 700-707. | 15.2 | 282 |
| 222 | Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors. <i>Oncogene</i> , 2011, 30, 757-769. | 2.6 | 70 |
| 223 | Exacerbated experimental autoimmune encephalomyelitis in mast-cell-deficient <i>Kit^{W-sh/W-sh}</i> mice. <i>Laboratory Investigation</i> , 2011, 91, 627-641. | 1.7 | 61 |
| 224 | Construction of a plasmid for co-expression of mouse membrane-bound form of IL-15 and RAE-1 μ and its biological activity. <i>Plasmid</i> , 2011, 65, 239-245. | 0.4 | 5 |
| 225 | IL-18 Induces PD-1-Dependent Immunosuppression in Cancer. <i>Cancer Research</i> , 2011, 71, 5393-5399. | 0.4 | 307 |
| 226 | Cytotoxic Dendritic Cells Generated from Cancer Patients. <i>Journal of Immunology</i> , 2011, 187, 2775-2782. | 0.4 | 23 |
| 227 | Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. <i>Seminars in Immunopathology</i> , 2011, 33, 369-383. | 2.8 | 265 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 228 | A distinct subset of human NK cells expressing HLA-DR expand in response to IL-2 and can aid immune responses to BCG. <i>European Journal of Immunology</i> , 2011, 41, 1924-1933. | 1.6 | 80 |
| 230 | MDC1 Cleavage by Caspase-3: A Novel Mechanism for Inactivating the DNA Damage Response during Apoptosis. <i>Cancer Research</i> , 2011, 71, 906-913. | 0.4 | 30 |
| 231 | Natural killer (NK)-dendritic cell interactions generate MHC class II-dressed NK cells that regulate CD4 ⁺ T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18360-18365. | 3.3 | 99 |
| 232 | The Inflammasomes. , 2011, , . | | 9 |
| 233 | Efficient Melanoma Cell Killing and Reduced Melanoma Growth in Mice by a Selective Replicating Adenovirus Armed with Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. <i>Human Gene Therapy</i> , 2011, 22, 405-417. | 1.4 | 13 |
| 234 | Natural killer cells in non-hematopoietic malignancies. <i>Frontiers in Immunology</i> , 2012, 3, 395. | 2.2 | 27 |
| 235 | Viral-induced encephalitis initiates distinct and functional CD103 ⁺ CD11b ⁺ brain dendritic cell populations within the olfactory bulb. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 6175-6180. | 3.3 | 39 |
| 236 | Dendritic Cells The Tumor Microenvironment and the Challenges for an Effective Antitumor Vaccination. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-15. | 3.0 | 67 |
| 237 | Efficient Xenoengraftment in Severe Immunodeficient NOD/Shi- <i>scid</i> IL2r ³ <i>null</i> Mice Is Attributed to a Lack of CD11c ⁺ B220 ⁺ CD122 ⁺ Cells. <i>Journal of Immunology</i> , 2012, 189, 4313-4320. | 0.4 | 22 |
| 238 | Dendritic Cells in Pathogenesis of COPD. <i>Current Pharmaceutical Design</i> , 2012, 18, 2329-2335. | 0.9 | 37 |
| 239 | Why do human B cells secrete granzyme B? Insights into a novel B-cell differentiation pathway. <i>Oncolmmunology</i> , 2012, 1, 1368-1375. | 2.1 | 74 |
| 240 | Redefining interferon-producing killer dendritic cells as a novel intermediate in NK-cell differentiation. <i>Blood</i> , 2012, 119, 4349-4357. | 0.6 | 30 |
| 241 | Sensing tissue damage. <i>Blood</i> , 2012, 119, 4346-4347. | 0.6 | 0 |
| 242 | IKDCs or B220 ⁺ NK cells are pre-mNK cells. <i>Blood</i> , 2012, 119, 4345-4346. | 0.6 | 12 |
| 243 | Inhibition of cyclooxygenase-2 enhances immunotherapy against experimental brain tumors. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1191-1199. | 2.0 | 23 |
| 244 | Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. <i>Blood</i> , 2012, 120, 3936-3944. | 0.6 | 80 |
| 245 | Deletion of cognate CD8 T cells by immature dendritic cells: a novel role for perforin, granzyme A, TREM-1, and TLR7. <i>Blood</i> , 2012, 120, 1647-1657. | 0.6 | 33 |
| 246 | An Immunosurveillance Mechanism Controls Cancer Cell Ploidy. <i>Science</i> , 2012, 337, 1678-1684. | 6.0 | 367 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 247 | Licensing of killer dendritic cells in mouse and humans: Functional similarities between IKDC and human blood β 1 T-lymphocytes. <i>Journal of Immunotoxicology</i> , 2012, 9, 259-266. | 0.9 | 6 |
| 248 | Granulocyte-macrophage stimulating factor (GM-CSF) increases circulating dendritic cells but does not abrogate suppression of adaptive cellular immunity in patients with metastatic colorectal cancer receiving chemotherapy. <i>Cancer Cell International</i> , 2012, 12, 2. | 1.8 | 10 |
| 250 | Heat shock protein 90 α (HSP90 α), a substrate and chaperone of DNA-PK necessary for the apoptotic response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 12866-12872. | 3.3 | 75 |
| 251 | Cancer-Induced Immunosuppression: IL-18 α -Elicited Immunoablative NK Cells. <i>Cancer Research</i> , 2012, 72, 2757-2767. | 0.4 | 95 |
| 252 | Essential roles of insulin expression in Aire $^+$ tolerogenic dendritic cells in maintaining peripheral self-tolerance of islet β -cells. <i>Cellular Immunology</i> , 2012, 273, 115-123. | 1.4 | 19 |
| 253 | Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2013, , . | 0.1 | 8 |
| 254 | An unconventional γ TRAIL to cancer therapy. <i>European Journal of Immunology</i> , 2013, 43, 3159-3162. | 1.6 | 8 |
| 255 | IL-17, IL-22 and Their Producing Cells: Role in Inflammation and Autoimmunity. , 2013, , . | | 1 |
| 256 | Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance. <i>Immunity</i> , 2013, 39, 74-88. | 6.6 | 739 |
| 257 | Immunosurveillance. , 2013, , 101-113. | | 2 |
| 258 | The mouse dendritic cell marker CD11c is down-regulated upon cell activation through Toll-like receptor triggering. <i>Immunobiology</i> , 2013, 218, 28-39. | 0.8 | 82 |
| 259 | Activated monocytes augment γ TRAIL-mediated cytotoxicity by human γ NK cells through release of γ IFN α . <i>European Journal of Immunology</i> , 2013, 43, 249-257. | 1.6 | 23 |
| 260 | Combining cancer immunotherapy and targeted therapy. <i>Current Opinion in Immunology</i> , 2013, 25, 291-296. | 2.4 | 59 |
| 261 | Combining Vaccines with Therapies that Render Tumor Cells more Susceptible to Immune Mediated Killing. , 2013, , 621-642. | | 0 |
| 262 | Human Cancer Resistance to Trail-Apoptotic Pathway-Targeted Therapies. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2013, , 213-243. | 0.1 | 0 |
| 263 | The Tumor Immunoenvironment. , 2013, , . | | 4 |
| 264 | Interleukin-21 expanded NKDC in vitro reduces the B16F10 tumor growth in vivo. <i>Cytokine</i> , 2013, 61, 154-160. | 1.4 | 6 |
| 265 | Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients. <i>Oncolmmunology</i> , 2013, 2, e23079. | 2.1 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 266 | Phase I clinical trial combining imatinib mesylate and IL-2. <i>Oncolimmunology</i> , 2013, 2, e23080. | 2.1 | 29 |
| 268 | Natural Killer Dendritic Cells Enhance Immune Responses Elicited by α -Galactosylceramide-Stimulated Natural Killer T Cells. <i>BioMed Research International</i> , 2013, 2013, 1-18. | 0.9 | 14 |
| 269 | Revisiting the Prominent Anti-Tumoral Potential of Pre-mNK Cells. <i>Frontiers in Immunology</i> , 2013, 4, 446. | 2.2 | 16 |
| 270 | Dendritic Cells in Human Pneumovirus and Metapneumovirus Infections. <i>Viruses</i> , 2013, 5, 1553-1570. | 1.5 | 7 |
| 271 | Novel immune modulators used in hematology: impact on NK cells. <i>Frontiers in Immunology</i> , 2013, 3, 388. | 2.2 | 43 |
| 272 | Trial watch. <i>Oncolimmunology</i> , 2013, 2, e25771. | 2.1 | 150 |
| 273 | Interleukin-15 in Gene Therapy of Cancer. <i>Current Gene Therapy</i> , 2013, 13, 15-30. | 0.9 | 37 |
| 274 | Modeling Leukocyte-Leukocyte Non-Contact Interactions in a Lymph Node. <i>PLoS ONE</i> , 2013, 8, e76756. | 1.1 | 0 |
| 275 | Trial watch: Dendritic cell-based anticancer therapy. <i>Oncolimmunology</i> , 2014, 3, e963424. | 2.1 | 62 |
| 277 | Flow Cytometric Detection of p38 MAPK Phosphorylation and Intracellular Cytokine Expression in Peripheral Blood Subpopulations from Patients with Autoimmune Rheumatic Diseases. <i>Journal of Immunology Research</i> , 2014, 2014, 1-13. | 0.9 | 6 |
| 278 | Immunomodulatory effect of poly- β -glutamic acid derived from <i>Bacillus subtilis</i> on natural killer dendritic cells. <i>Biochemical and Biophysical Research Communications</i> , 2014, 443, 413-421. | 1.0 | 13 |
| 279 | Natural Killer Cells: The Secret Weapon in Dendritic Cell Vaccination Strategies. <i>Clinical Cancer Research</i> , 2014, 20, 1095-1103. | 3.2 | 49 |
| 280 | Gene Therapy with Beta-Defensin 2 Induces Antitumor Immunity and Enhances Local Antitumor Effects. <i>Human Gene Therapy</i> , 2014, 25, 63-72. | 1.4 | 27 |
| 281 | The nuclear β -H2AX apoptotic ring: implications for cancers and autoimmune diseases. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 2289-2297. | 2.4 | 88 |
| 282 | Tumoricidal activity of human dendritic cells. <i>Trends in Immunology</i> , 2014, 35, 38-46. | 2.9 | 62 |
| 283 | MHCII-Mediated Dialog between Group 2 Innate Lymphoid Cells and CD4+ T Cells Potentiates Type 2 Immunity and Promotes Parasitic Helminth Expulsion. <i>Immunity</i> , 2014, 41, 283-295. | 6.6 | 601 |
| 284 | Interactions between innate and adaptive lymphocytes. <i>Nature Reviews Immunology</i> , 2014, 14, 631-639. | 10.6 | 175 |
| 285 | Tumor-Induced Immune Suppression. , 2014, , . | | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 286 | Nilotinib combined with interleukin-2 mediates antitumor and immunological effects in a B16 melanoma model. <i>Oncology Reports</i> , 2014, 31, 2015-2020. | 1.2 | 9 |
| 287 | Depletion of B220 ⁺ NK1.1 ⁺ cells enhances the rejection of established melanoma by tumor-specific CD4 ⁺ T cells. <i>Onc Immunology</i> , 2015, 4, e1019196. | 2.1 | 10 |
| 288 | Expansion of an Atypical NK Cell Subset in Mouse Models of Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2015, 194, 1503-1513. | 0.4 | 24 |
| 289 | Cutting Edge: Induction of Inflammatory Disease by Adoptive Transfer of an Atypical NK Cell Subset. <i>Journal of Immunology</i> , 2015, 195, 806-809. | 0.4 | 10 |
| 290 | Platelet-Derived Growth Factor Signaling in the Lung: From Lung Development and Disease to Clinical Studies. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2015, 52, 263-284. | 1.4 | 76 |
| 291 | Death ligands and granulysin: mechanisms of tumor cell death induction and therapeutic opportunities. <i>Immunotherapy</i> , 2015, 7, 883-882. | 1.0 | 22 |
| 292 | Perforin-Positive Dendritic Cells Exhibit an Immuno-regulatory Role in Metabolic Syndrome and Autoimmunity. <i>Immunity</i> , 2015, 43, 776-787. | 6.6 | 55 |
| 293 | TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. <i>Oncogene</i> , 2015, 34, 2138-2144. | 2.6 | 65 |
| 294 | Early Differentiation of Human CD11c ⁺ NK Cells with <i>β₂T</i> Cell Activation Properties Is Promoted by Dialyzable Leukocyte Extracts. <i>Journal of Immunology Research</i> , 2016, 2016, 1-12. | 0.9 | 16 |
| 295 | Extracellular HSPs: The Complicated Roles of Extracellular HSPs in Immunity. <i>Frontiers in Immunology</i> , 2016, 7, 159. | 2.2 | 155 |
| 296 | Immunological off-target effects of imatinib. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 431-446. | 12.5 | 120 |
| 297 | Resistance of novel mouse strains different in MHC class I and the NKC domain to the development of experimental tumors. <i>International Journal of Oncology</i> , 2016, 49, 763-772. | 1.4 | 5 |
| 298 | Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 74. | 3.5 | 42 |
| 299 | A role for pre-mNK cells in tumor progression. , 2016, 4, 16. | | 6 |
| 300 | CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model. <i>Cancer Letters</i> , 2016, 373, 88-96. | 3.2 | 31 |
| 301 | Radiotherapy and immunotherapy: a beneficial liaison?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 365-379. | 12.5 | 760 |
| 302 | Interferon- γ -inducible Dendritic Cells Matured with OK-432 Exhibit TRAIL and Fas Ligand Pathway-mediated Killer Activity. <i>Scientific Reports</i> , 2017, 7, 42145. | 1.6 | 12 |
| 303 | Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. <i>Science</i> , 2017, 356, . | 6.0 | 1,846 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 304 | Tumor abolition and antitumor immunostimulation by physico-chemical tumor ablation. <i>Frontiers in Bioscience - Landmark</i> , 2017, 22, 310-347. | 3.0 | 38 |
| 305 | Porcine NK cells display features associated with antigen-presenting cells. <i>Journal of Leukocyte Biology</i> , 2018, 103, 129-140. | 1.5 | 22 |
| 306 | The Secrets of T Cell Polarization. , 2018, , 69-95. | | 0 |
| 307 | Efficacy of combining ING4 and TRAIL genes in cancer-targeting gene virotherapy strategy: first evidence in preclinical hepatocellular carcinoma. <i>Gene Therapy</i> , 2018, 25, 54-65. | 2.3 | 19 |
| 308 | The 46th David A. Karnofsky Memorial Award Lecture: Oligometastasis—From Conception to Treatment. <i>Journal of Clinical Oncology</i> , 2018, 36, 3240-3250. | 0.8 | 49 |
| 309 | Regulatory IFN- γ -producing killer dendritic cells are enhanced in B6.MLR ^{Fas^{lpr}/J} lupus-prone mice. <i>European Journal of Immunology</i> , 2018, 48, 1851-1860. | 1.6 | 1 |
| 310 | The Dark Side of IFN- β : Its Role in Promoting Cancer Immuno-evasion. <i>International Journal of Molecular Sciences</i> , 2018, 19, 89. | 1.8 | 227 |
| 311 | Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific. <i>Nature Immunology</i> , 2018, 19, 885-897. | 7.0 | 152 |
| 312 | Glycolipid Stimulation of Invariant NKT Cells Expands a Unique Tissue-Resident Population of Precursors to Mature NK Cells Endowed with Oncolytic and Antimetastatic Properties. <i>Journal of Immunology</i> , 2019, 203, 1808-1819. | 0.4 | 6 |
| 313 | The Role of TRAIL/DRs in the Modulation of Immune Cells and Responses. <i>Cancers</i> , 2019, 11, 1469. | 1.7 | 40 |
| 314 | Effect of Multiple Vaccinations with Tumor Cell-Based Vaccine with Codon-Modified GM-CSF on Tumor Growth in a Mouse Model. <i>Cancers</i> , 2019, 11, 368. | 1.7 | 10 |
| 315 | Personalized Dendritic Cell Vaccines—Recent Breakthroughs and Encouraging Clinical Results. <i>Frontiers in Immunology</i> , 2019, 10, 766. | 2.2 | 132 |
| 316 | Natural killer cells limit the clearance of senescent lung adenocarcinoma cells. <i>Oncogenesis</i> , 2019, 8, 24. | 2.1 | 14 |
| 317 | Importance of TRAIL Molecular Anatomy in Receptor Oligomerization and Signaling. Implications for Cancer Therapy. <i>Cancers</i> , 2019, 11, 444. | 1.7 | 37 |
| 318 | CRTAM+ NK cells endowed with suppressor properties arise in leukemic bone marrow. <i>Journal of Leukocyte Biology</i> , 2019, 105, 999-1013. | 1.5 | 12 |
| 319 | IL-15 Generates IFN- β -producing Cells Reciprocally Expressing Lymphoid-Myeloid Markers during Dendritic Cell Differentiation. <i>International Journal of Biological Sciences</i> , 2019, 15, 464-480. | 2.6 | 8 |
| 320 | Beyond the vicious cycle: The role of innate osteoimmunity, automimicry and tumor-inherent changes in dictating bone metastasis. <i>Molecular Immunology</i> , 2019, 110, 57-68. | 1.0 | 21 |
| 321 | Imatinib modulates pro-inflammatory microenvironment with angiostatic effects in experimental lung carcinogenesis. <i>Inflammopharmacology</i> , 2020, 28, 231-252. | 1.9 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 322 | Imatinib exhibit synergistic pleiotropy in the prevention of colorectal cancer by suppressing proinflammatory, cell survival and angiogenic signaling. <i>Cellular Signalling</i> , 2020, 76, 109803. | 1.7 | 5 |
| 323 | Tumor-associated neutrophils suppress antitumor immunity of NK cells through the PD-L1/PD-1 axis. <i>Translational Oncology</i> , 2020, 13, 100825. | 1.7 | 50 |
| 324 | How does autophagy affect tumor-infiltrating immune cells?. , 2020, , 75-84. | | 0 |
| 325 | Maternal ̳3 docosapentaenoic acid inhibits infant allergic dermatitis through TRAIL-expressing plasmacytoid dendritic cells in mice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1939-1955. | 2.7 | 10 |
| 326 | IL-12 regulates the expansion, phenotype, and function of murine NK cells activated by IL-15 and IL-18. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1699-1712. | 2.0 | 39 |
| 327 | T-bet transduction enhances anti-tumor efficacy of IFN-producing dendritic cell (IKDC) against hepatocellular carcinoma via apoptosis induction. <i>Biochemical and Biophysical Research Communications</i> , 2021, 535, 80-86. | 1.0 | 4 |
| 328 | Phenotypical Diversification of Early IFN̳-Producing Human Plasmacytoid Dendritic Cells Using Droplet-Based Microfluidics. <i>Frontiers in Immunology</i> , 2021, 12, 672729. | 2.2 | 11 |
| 329 | Migration of dendritic cell subsets. , 2006, , 71-93. | | 1 |
| 330 | Tumor-Induced Immune Suppression. , 2008, , . | | 10 |
| 331 | THE NK/DC COMPLIT. <i>Advances in Experimental Medicine and Biology</i> , 2009, 633, 7-16. | 0.8 | 8 |
| 332 | Dendritic Cells: From Inducers of Specific T-Cell Responses to Promoters of Angiogenesis. , 2009, , 231-241. | | 1 |
| 333 | Immune-Mediated Tumor Rejection. , 2011, , 281-304. | | 2 |
| 334 | High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma. <i>Recent Results in Cancer Research</i> , 2011, 183, 207-238. | 1.8 | 2 |
| 335 | Effect of Chemotherapy on the Tumor Microenvironment and Anti-tumor Immunity. , 2013, , 1-28. | | 3 |
| 336 | Neonatal T Cell Immunity and Its Regulation by Innate Immunity and Dendritic Cells. , 2012, , 189-217. | | 1 |
| 337 | Dendritic cell-based vaccination: powerful resources of immature dendritic cells against pancreatic adenocarcinoma. <i>OncImmunology</i> , 2018, 7, e1504727. | 2.1 | 4 |
| 338 | Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. <i>Journal of Clinical Investigation</i> , 2009, 119, 2231-44. | 3.9 | 177 |
| 339 | T cell killing by tolerogenic dendritic cells protects mice from allergy. <i>Journal of Clinical Investigation</i> , 2011, 121, 3860-3871. | 3.9 | 31 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 340 | Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. <i>Journal of Clinical Investigation</i> , 2012, 122, 575-585. | 3.9 | 250 |
| 341 | Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. <i>Journal of Leukocyte Biology</i> , 2009, 86, 513-528. | 1.5 | 333 |
| 342 | Both Conventional and Interferon Killer Dendritic Cells Have Antigen-Presenting Capacity during Influenza Virus Infection. <i>PLoS ONE</i> , 2009, 4, e7187. | 1.1 | 36 |
| 343 | Interleukin-15-Induced CD56+ Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential. <i>PLoS ONE</i> , 2012, 7, e51851. | 1.1 | 48 |
| 344 | Dendritic Cell Tumor Killing Activity and Its Potential Applications in Cancer Immunotherapy. <i>Critical Reviews in Immunology</i> , 2013, 33, 1-21. | 1.0 | 38 |
| 345 | Cancer stem cells-driven tumor growth and immune escape: the Janus face of neurotrophins. <i>Aging</i> , 2019, 11, 11770-11792. | 1.4 | 25 |
| 347 | Dendritic Cells: Biological and Pathological Aspects. , 2008, , 409-427. | | 0 |
| 348 | General Properties of Dendritic Cell Populations in Cancer. , 2009, , 77-87. | | 0 |
| 349 | Targeting of TRAIL Apoptotic Pathways for Glioblastoma Therapies. , 2009, , 977-1009. | | 1 |
| 350 | Dendritic Cells in Cancer: Emergence of the Discipline. , 2009, , 11-30. | | 1 |
| 351 | NKG2D. The AFCS-nature Molecule Pages, 0, , . | 0.2 | 3 |
| 352 | Cancer, Inflammasomes, and Adjuvanticity. , 2011, , 151-163. | | 0 |
| 353 | Inflammation in Pulmonary Arterial Hypertension. , 2012, , 213-229. | | 1 |
| 354 | Role of IL-17 and IL-17 Family Cytokines on Tumor Development. , 2013, , 219-230. | | 0 |
| 356 | Immunobiology of Dendritic Cells in Cancer. , 2014, , 151-184. | | 2 |
| 357 | Cyclophosphamide, Fluorouracil and subcutaneous Interleukin-2 in the treatment of advanced GIST: A Case Report. <i>Surgical Case Reports</i> , 2019, , 1-5. | 0.0 | 0 |
| 359 | Signaling Pathways in Antigen-Presenting Cells Involved in the Induction of Antigen-Specific T-Cell Tolerance. , 2008, , 197-218. | | 0 |
| 361 | The Neoplastic Cell. , 0, , 756-793. | | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 362 | In vivo major histocompatibility complex class I (MHC I) expression on MHC I ^{low} tumor cells is regulated by gammadelta T and NK cells during the early steps of tumor growth. <i>Cancer Immunity</i> , 2009, 9, 10. | 3.2 | 17 |
| 363 | The innate immune system recognizes and regulates major histocompatibility complex class I (MHC I) expression on MHC I ^{low} tumor cells. <i>Cancer Immunity</i> , 2008, 8, 14. | 3.2 | 5 |
| 365 | Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST). <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 3563-79. | 0.5 | 19 |
| 368 | Fas/CD95 Signaling Pathway in Damage-Associated Molecular Pattern (DAMP)-Sensing Receptors. <i>Cells</i> , 2022, 11, 1438. | 1.8 | 6 |
| 372 | Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 4 |